Syndax Pharmaceuticals, Inc.SNDXNASDAQ
Loading
SNDX Revenue Growth (YoY Quarterly)•+791.68%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+791.68%
+524.7pp
+812.15%
+596.2pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.97%
-0.4pp
+0.97%
-0.4pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +984.51% | +266.97% | +791.68% |
| Gross Profit Growth | +0.00% | +0.00% | +947.97% | +215.94% | +812.15% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +18.30% | +0.48% | +1.25% | +1.39% | +0.97% |
| Weighted Average Shares Diluted Growth | +18.30% | +0.48% | +1.25% | +1.39% | +0.97% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +1030.48% | +183.18% | +243.91% | +441.64% | +173.92% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +8849.18% |
| Asset Growth | +18.26% | +17.99% | +24.99% | +29.59% | -26.92% |
| Book Value per Share Growth | -56.05% | -56.49% | -64.20% | -68.93% | -77.78% |
| Debt Growth | +21046.12% | +32.35% | +48.23% | +40348.59% | +0.22% |
| R&D Expense Growth | +18.87% | +9.11% | +27.89% | -20.70% | +20.01% |
| SG&A Expenses Growth | +65.46% | +78.23% | +50.73% | +44.40% | +32.47% |
1 / 4